{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:53:41Z","timestamp":1792115621329,"version":"4.4.0"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Opinion Statement<\/jats:title>\n          <jats:p>Pancreatic adenocarcinoma remains a leading cause of cancer-related mortality worldwide. Although surgery can be curable for a subset of patients, the five-year overall survival remains less than 15%. Despite extensive molecular characterization of pancreatic cancer, cytotoxic chemotherapy has served as the major component in therapeutic management. A major driver of pancreatic adenocarcinoma is mutations in KRAS, present in over 90% of cases. However, attempts to inhibit KRAS through upstream and downstream targets through the mitogen-activated protein kinase pathway have not been successful in the past. Despite this, multiple KRAS inhibitors have recently entered clinical trials and have shown promising results. These inhibitors have the potential to dramatically alter the landscape of treatment. In parallel, immunological approaches utilizing vaccines and bispecific antibodies are also in clinical development. Given these rapid new developments, the future of pancreatic cancer treatment will likely be determined by discovering the appropriate combinations of targeted and immune-based treatments.<\/jats:p>","DOI":"10.1007\/s11864-025-01352-2","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T07:00:30Z","timestamp":1756537230000},"page":"841-865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4381-0268","authenticated-orcid":false,"given":"Chengwei","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5918-6004","authenticated-orcid":false,"given":"Paul E.","family":"Oberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"1352_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1352_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.4708","volume":"4","author":"L Rahib","year":"2021","unstructured":"Rahib L, Wehner MR, Matrisian LM, Nead KT. Estimated projection of US cancer incidence and death to 2040. JAMA Netw Open. 2021;4: e214708\u2013214708.","journal-title":"JAMA Netw Open"},{"key":"1352_CR3","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA: A cancer. J Clin. 2025;75:10\u201345.","journal-title":"J Clin"},{"key":"1352_CR4","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1352_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13000-016-0497-z","volume":"11","author":"WM Hackeng","year":"2016","unstructured":"Hackeng WM, Hruban RH, Offerhaus GJA, Brosens LAA. Surgical and molecular pathology of pancreatic neoplasms. Diagn Pathol. 2016;11:47.","journal-title":"Diagn Pathol"},{"key":"1352_CR6","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/MPA.0000000000001338","volume":"48","author":"G Luo","year":"2019","unstructured":"Luo G, et al. Characteristics and outcomes of pancreatic cancer by histological subtypes. Pancreas. 2019;48:817\u201322.","journal-title":"Pancreas"},{"key":"1352_CR7","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40:1220\u201330.","journal-title":"J Clin Oncol"},{"key":"1352_CR8","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406.","journal-title":"N Engl J Med"},{"key":"1352_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011\u201324.","journal-title":"Lancet"},{"key":"1352_CR10","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"1352_CR11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DDV Hoff","year":"2013","unstructured":"Hoff DDV, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"1352_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01366-1","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, et al. Nalirifox versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023. https:\/\/doi.org\/10.1016\/S0140-6736(23)01366-1.","journal-title":"Lancet"},{"key":"1352_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327.","journal-title":"N Engl J Med"},{"key":"1352_CR14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545\u201357.","journal-title":"Lancet"},{"key":"1352_CR15","unstructured":"SEER*Explorer. An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program. 2025. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Accessed 20 Aug 2025."},{"key":"1352_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamasurg.2019.2277","volume":"154","author":"L Maggino","year":"2019","unstructured":"Maggino L, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154:932\u201342.","journal-title":"JAMA Surg"},{"key":"1352_CR17","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","volume":"154","author":"RP Jones","year":"2019","unstructured":"Jones RP, et al. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg. 2019;154:1038\u201348.","journal-title":"JAMA Surg"},{"key":"1352_CR18","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","volume":"186","author":"CJ Halbrook","year":"2023","unstructured":"Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A. Pancreatic cancer: advances and challenges. Cell. 2023;186:1729\u201354.","journal-title":"Cell"},{"key":"1352_CR19","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41575-020-0300-1","volume":"17","author":"AN Hosein","year":"2020","unstructured":"Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17:487\u2013505.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1352_CR20","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.1002\/cncr.32423","volume":"125","author":"GT Moffat","year":"2019","unstructured":"Moffat GT, Epstein AS, O\u2019Reilly EM. Pancreatic cancer-a disease in need: optimizing and integrating supportive care. Cancer. 2019;125:3927\u201335.","journal-title":"Cancer"},{"key":"1352_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1200\/JCO.2021.39.3_suppl.399","volume":"39","author":"CC Li","year":"2021","unstructured":"Li CC, et al. Sepsis and pancreatic cancer: biliary stents a significant risk factor in patients undergoing chemotherapy. J Clin Oncol. 2021;39:399\u2013399.","journal-title":"J Clin Oncol"},{"key":"1352_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102646","volume":"121","author":"JM Berger","year":"2023","unstructured":"Berger JM, Preusser M, Berghoff AS, Bergen ES. Malignant ascites: current therapy options and treatment prospects. Cancer Treat Rev. 2023;121: 102646.","journal-title":"Cancer Treat Rev"},{"key":"1352_CR23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","volume":"32","author":"Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma","year":"2017","unstructured":"Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017;32:185\u2013e203113.","journal-title":"Cancer Cell"},{"key":"1352_CR24","doi-asserted-by":"publisher","first-page":"6744","DOI":"10.1038\/ncomms7744","volume":"6","author":"AK Witkiewicz","year":"2015","unstructured":"Witkiewicz AK, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744\u20136744.","journal-title":"Nat Commun"},{"key":"1352_CR25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey P, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47\u201352.","journal-title":"Nature"},{"key":"1352_CR26","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1016\/j.cell.2021.08.023","volume":"184","author":"L Cao","year":"2021","unstructured":"Cao L, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021;184:5031\u2013e50525026.","journal-title":"Cell"},{"key":"1352_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature11547","volume":"491","author":"AV Biankin","year":"2012","unstructured":"Biankin AV, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399\u2013405.","journal-title":"Nature"},{"key":"1352_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518:495\u2013501.","journal-title":"Nature"},{"key":"1352_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41575-019-0109-y","volume":"16","author":"EA Collisson","year":"2019","unstructured":"Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16:207\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1352_CR30","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","volume":"24","author":"KL Aung","year":"2018","unstructured":"Aung KL, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24:1344\u201354.","journal-title":"Clin Cancer Res"},{"key":"1352_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11\u201322.","journal-title":"Nat Rev Cancer"},{"key":"1352_CR32","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","volume":"26","author":"AS Dhillon","year":"2007","unstructured":"Dhillon AS, Hagan S, Rath O, Kolch W. Map kinase signalling pathways in cancer. Oncogene. 2007;26:3279\u201390.","journal-title":"Oncogene"},{"key":"1352_CR33","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548\u201351.","journal-title":"Nature"},{"key":"1352_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2022","unstructured":"Strickler JH, et al. Sotorasib in KRAS p.G12C\u2013Mutated advanced pancreatic cancer. N Engl J Med. 2022;388:33\u201343.","journal-title":"N Engl J Med"},{"key":"1352_CR35","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab TS, et al. Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation. J Clin Oncol. 2023;41:4097\u2013106.","journal-title":"J Clin Oncol"},{"key":"1352_CR36","unstructured":"NCCN Clinical practice guidelines in oncology: pancreatic adenocarcinoma. Version 2.2025. Accessed 20 Aug 2025."},{"key":"1352_CR37","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"A Sacher","year":"2023","unstructured":"Sacher A, et al. Single-Agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med. 2023;389:710\u201321.","journal-title":"N Engl J Med"},{"key":"1352_CR38","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1200\/JCO.2024.42.3_suppl.604","volume":"42","author":"J Li","year":"2024","unstructured":"Li J, et al. Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors. J Clin Oncol. 2024;42:604\u2013604.","journal-title":"J Clin Oncol"},{"key":"1352_CR39","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1200\/JCO.2025.43.4_suppl.724","volume":"43","author":"AI Spira","year":"2025","unstructured":"Spira AI, et al. Preliminary safety, antitumor activity, and Circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. J Clin Oncol. 2025;43:724\u2013724.","journal-title":"J Clin Oncol"},{"key":"1352_CR40","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.annonc.2023.10.025","volume":"34","author":"C Zhou","year":"2023","unstructured":"Zhou C, et al. LBA33 A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation. Ann Oncol. 2023;34:1273.","journal-title":"Ann Oncol"},{"key":"1352_CR41","doi-asserted-by":"publisher","first-page":"S486","DOI":"10.1016\/j.annonc.2024.08.675","volume":"35","author":"W Park","year":"2024","unstructured":"Park W, et al. 608O preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC). Ann Oncol. 2024;35:S486\u20137.","journal-title":"Ann Oncol"},{"key":"1352_CR42","unstructured":"Silexion therapeutics announces significant new data from phase 2 trial of LODER\u2122 in non-resectable pancreatic cancer. 2024. https:\/\/silexion.com\/wp-content\/uploads\/2024\/09\/SLXN-FINAL-PR-_-240924.pdf. Accessed 20 Aug 2025."},{"key":"1352_CR43","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","volume":"42","author":"C Zhou","year":"2024","unstructured":"Zhou C, et al. Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome Inhibition in KRAS G12D-mutant cancer. Cancer Cell. 2024;42:1286\u2013e13001288.","journal-title":"Cancer Cell"},{"key":"1352_CR44","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.cell.2020.09.044","volume":"183","author":"D Kim","year":"2020","unstructured":"Kim D, Xue JY, Lito P. Targeting. KRAS(G12C): from inhibitory mechanism to modulation of antitumor effects in patients. Cell. 2020;183:850\u20139.","journal-title":"Cell"},{"key":"1352_CR45","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med. 2022;28:2171\u201382.","journal-title":"Nat Med"},{"key":"1352_CR46","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang X, et al. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J Med Chem. 2022;65:3123\u201333.","journal-title":"J Med Chem"},{"key":"1352_CR47","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","volume":"13","author":"SB Kemp","year":"2023","unstructured":"Kemp SB, et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 2023;13:298\u2013311.","journal-title":"Cancer Discov"},{"key":"1352_CR48","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan KK, et al. KRASG12D Inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells. Cancer Cell. 2023;41:1606\u2013e16201608.","journal-title":"Cancer Cell"},{"key":"1352_CR49","doi-asserted-by":"publisher","first-page":"TPS764","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS764","volume":"41","author":"AW Tolcher","year":"2023","unstructured":"Tolcher AW, et al. Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations. J Clin Oncol. 2023;41:TPS764\u2013764.","journal-title":"J Clin Oncol"},{"key":"1352_CR50","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1200\/JCO.2025.43.4_suppl.722","volume":"43","author":"I Garrido-Laguna","year":"2025","unstructured":"Garrido-Laguna I, et al. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2025;43:722\u2013722.","journal-title":"J Clin Oncol"},{"key":"1352_CR51","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1538-7445.AM2021-1260","volume":"81","author":"E Koltun","year":"2021","unstructured":"Koltun E, et al. Abstract 1260: first-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers. Cancer Res. 2021;81:1260\u20131260.","journal-title":"Cancer Res"},{"key":"1352_CR52","doi-asserted-by":"publisher","first-page":"20723","DOI":"10.1073\/pnas.1314307110","volume":"110","author":"E Zorde Khvalevsky","year":"2013","unstructured":"Zorde Khvalevsky E, et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110:20723\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1352_CR53","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang J, et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 2024;14:994\u20131017.","journal-title":"Cancer Discov"},{"key":"1352_CR54","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.PANCA2023-C084","volume":"84","author":"BG Smaglo","year":"2024","unstructured":"Smaglo BG, et al. Abstract C084: iexplore: a phase I study of mesenchymal stem cell derived exosomes with KrasG12D siRNA for metastatic pancreas cancer patients harboring the KrasG12D mutation. Cancer Res. 2024;84: C084\u2013084.","journal-title":"Cancer Res"},{"key":"1352_CR55","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, et al. Acquired resistance to KRASG12C inhibition in cancer. N Engl J Med. 2021;384:2382\u201393.","journal-title":"N Engl J Med"},{"key":"1352_CR56","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021;599:679\u201383.","journal-title":"Nature"},{"key":"1352_CR57","doi-asserted-by":"publisher","DOI":"10.1172\/JCI155523","author":"YS Tsai","year":"2022","unstructured":"Tsai YS, et al. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI155523.","journal-title":"J Clin Invest"},{"key":"1352_CR58","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.jtho.2022.07.022","volume":"17","author":"G Falchook","year":"2022","unstructured":"Falchook G, et al. OA03.03 Sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-Mutated NSCLC and other solid tumors. J Thorac Oncol. 2022;17:S8.","journal-title":"J Thorac Oncol"},{"key":"1352_CR59","doi-asserted-by":"publisher","first-page":"S902","DOI":"10.1016\/j.annonc.2023.09.2579","volume":"34","author":"AC Kanhailal","year":"2023","unstructured":"Kanhailal AC, et al. 1630P phase i\/ib study of SHP2-ERK Inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers. Ann Oncol. 2023;34:S902\u20133.","journal-title":"Ann Oncol"},{"key":"1352_CR60","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1093\/oncolo\/oyac237","volume":"28","author":"PM Grierson","year":"2023","unstructured":"Grierson PM, et al. Phase Ib study of Ulixertinib plus gemcitabine and Nab-Paclitaxel in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2023;28:e115\u201323.","journal-title":"Oncologist"},{"key":"1352_CR61","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1200\/JCO.2024.42.16_suppl.4140","volume":"42","author":"K-H Lim","year":"2024","unstructured":"Lim K-H, et al. Avutometinib\/defactinib and gemcitabine\/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: initial safety and efficacy of phase 1b\/2 study (RAMP 205). J Clin Oncol. 2024;42:4140\u20134140.","journal-title":"J Clin Oncol"},{"key":"1352_CR62","unstructured":"Immuneering Announces Positive Initial. Phase 2a data including complete and partial responses with IMM-1-104 in combination with chemotherapy in first-line pancreatic cancer patients. 2024. https:\/\/ir.immuneering.com\/news-releases\/news-release-details\/immuneering-announces-positive-initial-phase-2a-data-including. Accessed 20 Aug 2025."},{"key":"1352_CR63","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.ccell.2022.07.005","volume":"40","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, et al. A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. Cancer Cell. 2022;40:1060\u2013e10691067.","journal-title":"Cancer Cell"},{"key":"1352_CR64","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1158\/2159-8290.CD-22-1074","volume":"13","author":"T Hattori","year":"2023","unstructured":"Hattori T, et al. Creating MHC-restricted neoantigens with covalent inhibitors that can be targeted by immune therapy. Cancer Discov. 2023;13:132\u201345.","journal-title":"Cancer Discov"},{"key":"1352_CR65","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","volume":"156","author":"AD Singhi","year":"2019","unstructured":"Singhi AD, et al. Real-Time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology. 2019;156:2242\u2013e22532244.","journal-title":"Gastroenterology"},{"key":"1352_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01732-6","volume":"39","author":"C Luchini","year":"2020","unstructured":"Luchini C, et al. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. J Exp Clin Cancer Res. 2020;39: 227.","journal-title":"J Exp Clin Cancer Res"},{"key":"1352_CR67","doi-asserted-by":"publisher","unstructured":"Fusco MJ, et al. Identification of targetable gene fusions and structural rearrangements to foster precision medicine in KRAS wild-type pancreatic cancer. JCO Precis Oncol. 2021;5. https:\/\/doi.org\/10.1200\/po.20.00265.","DOI":"10.1200\/po.20.00265"},{"key":"1352_CR68","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/2159-8290.CD-18-0036","volume":"8","author":"C Heining","year":"2018","unstructured":"Heining C, et al. NRG1 fusions in KRAS wild-type pancreatic cancer. Cancer Discov. 2018;8:1087\u201395.","journal-title":"Cancer Discov"},{"key":"1352_CR69","unstructured":"FDA grants accelerated. Approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma. 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic. Accessed 20 Aug 2025."},{"key":"1352_CR70","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1056\/NEJMoa2405008","volume":"392","author":"AM Schram","year":"2025","unstructured":"Schram AM, et al. Efficacy of zenocutuzumab in NRG1 fusion-positive cancer. N Engl J Med. 2025;392:566\u201376.","journal-title":"N Engl J Med"},{"key":"1352_CR71","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1200\/JCO.2018.36.4_suppl.521","volume":"36","author":"MJ Pishvaian","year":"2018","unstructured":"Pishvaian MJ, et al. Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions. J Clin Oncol. 2018;36:521\u2013521.","journal-title":"J Clin Oncol"},{"key":"1352_CR72","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele RC, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials. Lancet Oncol. 2020;21:271\u201382.","journal-title":"Lancet Oncol"},{"key":"1352_CR73","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1634\/theoncologist.2016-0194","volume":"22","author":"Y Shimada","year":"2017","unstructured":"Shimada Y, et al. An oncogenic ALK fusion and an RRAS mutation in KRAS mutation-negative pancreatic ductal adenocarcinoma. Oncologist. 2017;22:158\u201364.","journal-title":"Oncologist"},{"key":"1352_CR74","doi-asserted-by":"publisher","first-page":"5163","DOI":"10.1200\/JCO.22.02630","volume":"41","author":"S Qin","year":"2023","unstructured":"Qin S, et al. Nimotuzumab plus gemcitabine for K-Ras wild-type locally advanced or metastatic pancreatic cancer. J Clin Oncol. 2023;41:5163\u201373.","journal-title":"J Clin Oncol"},{"key":"1352_CR75","doi-asserted-by":"publisher","unstructured":"Philip PA et al. Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res, OF1-OF11. 2022. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3581.","DOI":"10.1158\/1078-0432.Ccr-21-3581"},{"key":"1352_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103897","volume":"77","author":"X Zhang","year":"2022","unstructured":"Zhang X, et al. Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer. EBioMedicine. 2022;77: 103897.","journal-title":"EBioMedicine"},{"key":"1352_CR77","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694\u2013703.","journal-title":"N Engl J Med"},{"key":"1352_CR78","doi-asserted-by":"publisher","unstructured":"Hendifar A et al. Retrospective case series analysis of RAF family alterations in pancreatic cancer: Real-World outcomes from targeted and standard therapies. JCO Precision Oncol. 2021; 1325\u201338. https:\/\/doi.org\/10.1200\/po.20.00494.","DOI":"10.1200\/po.20.00494"},{"key":"1352_CR79","doi-asserted-by":"publisher","DOI":"10.1093\/gastro\/goab031","author":"H-S Li","year":"2021","unstructured":"Li H-S, Yang K, Wang Y. Remarkable response of BRAFV600E-mutated metastatic pancreatic cancer to BRAF\/MEK inhibition: a case report. Gastroenterol Rep. 2021. https:\/\/doi.org\/10.1093\/gastro\/goab031.","journal-title":"Gastroenterol Rep"},{"key":"1352_CR80","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1159\/000510096","volume":"13","author":"S Sasankan","year":"2020","unstructured":"Sasankan S, Rebuck L, Darrah G, Harari Turquie M, Rabinowitz I. Metastatic pancreatic cancer with BRAF and P53 mutations: case report of therapeutic response to doublet targeted therapy. Case Rep Oncol. 2020;13:1239\u201343.","journal-title":"Case Rep Oncol"},{"key":"1352_CR81","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217\u201323.","journal-title":"Nature"},{"key":"1352_CR82","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jtho.2022.07.025","volume":"17","author":"BT Li","year":"2022","unstructured":"Li BT, et al. OA03.06 codebreak 100\/101: first report of safety\/efficacy of Sotorasib in combination with pembrolizumab or Atezolizumab in advanced KRAS p.G12C NSCLC. J Thorac Oncol. 2022;17:S10\u20131.","journal-title":"J Thorac Oncol"},{"key":"1352_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100360","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, et al. LBA4 preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-naive patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Immuno-Oncology and Technology. 2022. https:\/\/doi.org\/10.1016\/j.iotech.2022.100360.","journal-title":"Immuno-Oncology and Technology"},{"key":"1352_CR84","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.20.03238","volume":"39","author":"R Casolino","year":"2021","unstructured":"Casolino R, et al. Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. J Clin Oncol. 2021;39:2617\u201331.","journal-title":"J Clin Oncol"},{"key":"1352_CR85","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","volume":"21","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian MJ, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the know your tumor registry trial. Lancet Oncol. 2020;21:508\u201318.","journal-title":"Lancet Oncol"},{"key":"1352_CR86","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","volume":"26","author":"W Park","year":"2020","unstructured":"Park W, et al. Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. 2020;26:3239\u201347.","journal-title":"Clin Cancer Res"},{"key":"1352_CR87","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","volume":"122","author":"MM Wattenberg","year":"2020","unstructured":"Wattenberg MM, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2020;122:333\u20139.","journal-title":"Br J Cancer"},{"key":"1352_CR88","doi-asserted-by":"publisher","unstructured":"Reiss KA et al. Retrospective survival analysis of patients with advanced pancreatic ductal adenocarcinoma and germline BRCA or PALB2 mutations. JCO Precision Oncol. 2018; 1\u20139. https:\/\/doi.org\/10.1200\/po.17.00152.","DOI":"10.1200\/po.17.00152"},{"key":"1352_CR89","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/bjc.2014.418","volume":"111","author":"T Golan","year":"2014","unstructured":"Golan T, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111:1132\u20138.","journal-title":"Br J Cancer"},{"key":"1352_CR90","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/PPO.0000000000000554","volume":"27","author":"TJ Brown","year":"2021","unstructured":"Brown TJ, Reiss KA. PARP inhibitors in pancreatic cancer. Cancer J. 2021;27:465\u201375.","journal-title":"Cancer J"},{"key":"1352_CR91","first-page":"551","volume":"34","author":"F Muggia","year":"2014","unstructured":"Muggia F, Safra T. BRCAness\u2019 and its implications for platinum action in gynecologic cancer. Anticancer Res. 2014;34:551\u20136.","journal-title":"Anticancer Res"},{"key":"1352_CR92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01604","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.21.01604.","journal-title":"J Clin Oncol"},{"key":"1352_CR93","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.21.00003","volume":"39","author":"KA Reiss","year":"2021","unstructured":"Reiss KA, et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39:2497\u2013505.","journal-title":"J Clin Oncol"},{"key":"1352_CR94","doi-asserted-by":"publisher","first-page":"6314","DOI":"10.1158\/1078-0432.CCR-21-1789","volume":"27","author":"EG Chiorean","year":"2021","unstructured":"Chiorean EG, et al. Randomized phase II study of PARP inhibitor ABT-888 (Veliparib) with modified FOLFIRI versus FOLFIRI as second-line treatment of metastatic pancreatic cancer: SWOG S1513. Clin Cancer Res. 2021;27:6314\u201322.","journal-title":"Clin Cancer Res"},{"key":"1352_CR95","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","volume":"23","author":"KA Reiss","year":"2022","unstructured":"Reiss KA, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial. Lancet Oncol. 2022;23:1009\u201320.","journal-title":"Lancet Oncol"},{"key":"1352_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1567","volume":"35","author":"W Park","year":"2024","unstructured":"Park W, et al. 1504MO phase II trial of pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum. Ann Oncol. 2024;35: S922.","journal-title":"Ann Oncol"},{"key":"1352_CR97","doi-asserted-by":"publisher","first-page":"TPS793","DOI":"10.1200\/JCO.2025.43.4_suppl.TPS793","volume":"43","author":"V Chung","year":"2025","unstructured":"Chung V, et al. Randomized phase II trial of Olaparib\u2009+\u2009pembrolizumab vs Olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations: SWOG S2001 NCT04548752. J Clin Oncol. 2025;43:TPS793-793.","journal-title":"J Clin Oncol"},{"key":"1352_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2022.0611","volume":"8","author":"G Terrero","year":"2022","unstructured":"Terrero G, et al. Ipilimumab\/Nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants. JAMA Oncol. 2022;8:1\u20133.","journal-title":"JAMA Oncol"},{"key":"1352_CR99","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1053\/j.gastro.2021.01.220","volume":"160","author":"T Golan","year":"2021","unstructured":"Golan T, et al. Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma. Gastroenterology. 2021;160:2119\u2013e21322119.","journal-title":"Gastroenterology"},{"key":"1352_CR100","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.3390\/cancers13184716","volume":"13","author":"MM Wattenberg","year":"2021","unstructured":"Wattenberg MM, Reiss KA. Determinants of homologous recombination deficiency in pancreatic cancer. Cancers. 2021;13:4716.","journal-title":"Cancers"},{"key":"1352_CR101","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","volume":"17","author":"Y Wallez","year":"2018","unstructured":"Wallez Y, et al. The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. Mol Cancer Ther. 2018;17:1670\u201382.","journal-title":"Mol Cancer Ther"},{"key":"1352_CR102","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","volume":"39","author":"RL Lloyd","year":"2020","unstructured":"Lloyd RL, et al. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene. 2020;39:4869\u201383.","journal-title":"Oncogene"},{"key":"1352_CR103","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","volume":"28","author":"G Illuzzi","year":"2022","unstructured":"Illuzzi G, et al. Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper. Clin Cancer Res. 2022;28:4724\u201336.","journal-title":"Clin Cancer Res"},{"key":"1352_CR104","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/gutjnl-2018-316451","volume":"68","author":"A Neesse","year":"2019","unstructured":"Neesse A, et al. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut. 2019;68:159\u201371.","journal-title":"Gut"},{"key":"1352_CR105","doi-asserted-by":"publisher","unstructured":"Ferrara B et al. The extracellular matrix in pancreatic cancer: description of a complex network and promising therapeutic options. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13174442.","DOI":"10.3390\/cancers13174442"},{"key":"1352_CR106","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/1756283X13478680","volume":"6","author":"PE Oberstein","year":"2013","unstructured":"Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Ther Adv Gastroenterol. 2013;6:321\u201337.","journal-title":"Ther Adv Gastroenterol"},{"key":"1352_CR107","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1146\/annurev-cancerbio-061421-035400","volume":"7","author":"MH Sherman","year":"2023","unstructured":"Sherman MH, Magliano MP. D. cancer-associated fibroblasts: lessons from pancreatic cancer. Annu Rev Cancer Biol. 2023;7:43\u201355.","journal-title":"Annu Rev Cancer Biol"},{"key":"1352_CR108","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1158\/2159-8290.CD-21-0601","volume":"12","author":"EJ Helms","year":"2022","unstructured":"Helms EJ, et al. Mesenchymal lineage heterogeneity underlies nonredundant functions of pancreatic cancer-associated fibroblasts. Cancer Discov. 2022;12:484\u2013501.","journal-title":"Cancer Discov"},{"key":"1352_CR109","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","volume":"17","author":"WJ Ho","year":"2020","unstructured":"Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer \u2014 clinical challenges and opportunities. Nat Rev Clin Oncol. 2020;17:527\u201340.","journal-title":"Nat Rev Clin Oncol"},{"key":"1352_CR110","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.20.00590","volume":"38","author":"EV Cutsem","year":"2020","unstructured":"Cutsem EV, et al. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J Clin Oncol. 2020;38:3185\u201394.","journal-title":"J Clin Oncol"},{"key":"1352_CR111","unstructured":"Ryan C. Novartis discontinues development of NIS793 in pancreatic cancer. 2023. https:\/\/www.onclive.com\/view\/novartis-discontinues-development-of-nis793-in-pancreatic-cancer. Accessed 20 Aug 2025."},{"key":"1352_CR112","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1200\/JCO.2025.43.4_suppl.675","volume":"43","author":"VJ Picozzi","year":"2025","unstructured":"Picozzi VJ, et al. Randomized phase 3 trial of chemotherapy (CTX) with and without Pamrevlumab (PAM) for locally advanced pancreatic cancer (LAPC). J Clin Oncol. 2025;43:675\u2013675.","journal-title":"J Clin Oncol"},{"key":"1352_CR113","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1200\/JCO.2025.43.4_suppl.673","volume":"43","author":"VJ Picozzi","year":"2025","unstructured":"Picozzi VJ, et al. Pamrevlumab plus nab-paclitaxel\/gemcitabine (Pam\u2009+\u2009GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): results from precision promise (PrP) bayesian platform trial. J Clin Oncol. 2025;43:673\u2013673.","journal-title":"J Clin Oncol"},{"key":"1352_CR114","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e16337","volume":"42","author":"C Burns","year":"2024","unstructured":"Burns C, et al. Phase 1b\/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): interim analysis. J Clin Oncol. 2024;42: e16337\u201316337.","journal-title":"J Clin Oncol"},{"key":"1352_CR115","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1136\/gutjnl-2020-320726","volume":"70","author":"C Luchini","year":"2021","unstructured":"Luchini C, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. 2021;70:148\u201356.","journal-title":"Gut"},{"key":"1352_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1\u201310.","journal-title":"J Clin Oncol"},{"key":"1352_CR117","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1200\/JCO.2024.42.16_suppl.4144","volume":"42","author":"CA O\u2019Connor","year":"2024","unstructured":"O\u2019Connor CA, et al. Somatic mismatch repair deficiency in pancreas cancer (PC): immune checkpoint Blockade (ICB) outcomes and exploratory genomic analyses. J Clin Oncol. 2024;42:4144\u20134144.","journal-title":"J Clin Oncol"},{"key":"1352_CR118","doi-asserted-by":"publisher","unstructured":"Coston T et al. Efficacy of immune checkpoint inhibition and cytotoxic chemotherapy in mismatch repair-deficient and microsatellite instability-high pancreatic cancer: mayo clinic experience. JCO Precision Oncol. 2023; e2200706. https:\/\/doi.org\/10.1200\/po.22.00706.","DOI":"10.1200\/po.22.00706"},{"key":"1352_CR119","unstructured":"Actuate Therapeutics Announces Positive Interim. Phase 2 data of Elraglusib in first line treatment of metastatic pancreatic cancer. 2024. https:\/\/actuatetherapeutics.com\/press_releases\/actuate-therapeutics-announces-positive-interim-phase-2-data-of-elraglusib-in-first-line-treatment-of-metastatic-pancreatic-cancer\/. Accessed 20 Aug 2025."},{"key":"1352_CR120","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1200\/JCO.2022.40.16_suppl.4141","volume":"40","author":"EV Cutsem","year":"2022","unstructured":"Cutsem EV, et al. Phase 1\/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with gemcitabine and nab-paclitaxel (GN) in patients with pancreatic adenocarcinoma (PDAC). J Clin Oncol. 2022;40:4141\u20134141.","journal-title":"J Clin Oncol"},{"key":"1352_CR121","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padr\u00f3n","year":"2022","unstructured":"Padr\u00f3n LJ, et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28:1167\u201377.","journal-title":"Nat Med"},{"key":"1352_CR122","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(24)00263-8","volume":"25","author":"J-L Van Laethem","year":"2024","unstructured":"Van Laethem J-L, et al. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b\/2 study. Lancet Oncol. 2024;25:853\u201364.","journal-title":"Lancet Oncol"},{"key":"1352_CR123","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1158\/1078-0432.CCR-06-0196","volume":"12","author":"AV Ougolkov","year":"2006","unstructured":"Ougolkov AV, et al. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res. 2006;12:5074\u201381.","journal-title":"Clin Cancer Res"},{"key":"1352_CR124","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries CH, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25:846\u201359.","journal-title":"Cancer Cell"},{"key":"1352_CR125","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.1158\/0008-5472.CAN-21-3603","volume":"81","author":"WJ Ho","year":"2021","unstructured":"Ho WJ, Jaffee EM. Macrophage-targeting by CSF1\/1R blockade in pancreatic cancers. Cancer Res. 2021;81:6071\u20133.","journal-title":"Cancer Res"},{"key":"1352_CR126","doi-asserted-by":"publisher","first-page":"eadd1834","DOI":"10.1126\/scitranslmed.add1834","volume":"16","author":"A Voissi\u00e8re","year":"2024","unstructured":"Voissi\u00e8re A, et al. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and May antagonize durvalumab effect in patients with advanced cancers. Sci Transl Med. 2024;16:eadd1834.","journal-title":"Sci Transl Med"},{"key":"1352_CR127","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10637-019-00830-3","volume":"38","author":"M Noel","year":"2020","unstructured":"Noel M, et al. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel\/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest New Drugs. 2020;38:800\u201311.","journal-title":"Invest New Drugs"},{"key":"1352_CR128","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","volume":"17","author":"TM Nywening","year":"2016","unstructured":"Nywening TM, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. Lancet Oncol. 2016;17:651\u201362.","journal-title":"Lancet Oncol"},{"key":"1352_CR129","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110:20212\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1352_CR130","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-19-0081","volume":"25","author":"YD Seo","year":"2019","unstructured":"Seo YD, et al. Mobilization of CD8\u2009+\u2009T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer. Clin Cancer Res. 2019;25:3934\u201345.","journal-title":"Clin Cancer Res"},{"key":"1352_CR131","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s00262-013-1427-5","volume":"62","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide RH, et al. CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother. 2013;62:949\u201354.","journal-title":"Cancer Immunol Immunother"},{"key":"1352_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061427","volume":"9","author":"G Augello","year":"2020","unstructured":"Augello G, et al. The role of GSK-3 in cancer immunotherapy: GSK-3 inhibitors as a new frontier in cancer treatment. Cells. 2020;9: 1427.","journal-title":"Cells"},{"key":"1352_CR133","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/0008-5472.CAN-19-2080","volume":"80","author":"S Das","year":"2020","unstructured":"Das S, Shapiro B, Vucic EA, Vogt S, Bar-Sagi D. Tumor cell-derived IL1\u03b2 promotes desmoplasia and immune suppression in pancreatic cancer. Cancer Res. 2020;80:1088\u2013101.","journal-title":"Cancer Res"},{"key":"1352_CR134","unstructured":"Elevation oncology receives fast track designation from the FDA for EO-3021 for the treatment of adult patients with advanced or metastatic gastric or gastroesophageal junction cancer expressing Claudin 18.2. 2024. https:\/\/investors.elevationoncology.com\/2024-09-23-Elevation-Oncology-Receives-Fast-Track-Designation-from-the-FDA-for-EO-3021-for-the-Treatment-of-Adult-Patients-with-Advanced-or-Metastatic-Gastric-or-Gastroesophageal-Junction-Cancer-Expressing-Claudin-18-2. Accessed 20 Aug 2025."},{"key":"1352_CR135","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1200\/JCO.2024.42.16_suppl.3028","volume":"42","author":"C Bai","year":"2024","unstructured":"Bai C, et al. A phase 1\/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric\/gastroesophageal junction cancer. J Clin Oncol. 2024;42:3028\u20133028.","journal-title":"J Clin Oncol"},{"key":"1352_CR136","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"D-Y Ruan","year":"2025","unstructured":"Ruan D-Y, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025;26:227\u201338.","journal-title":"Lancet Oncol"},{"key":"1352_CR137","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1200\/JCO.2024.42.16_suppl.3037","volume":"42","author":"X Yu","year":"2024","unstructured":"Yu X, et al. Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: preliminary results from a phase 1 study. J Clin Oncol. 2024;42:3037\u20133037.","journal-title":"J Clin Oncol"},{"key":"1352_CR138","doi-asserted-by":"publisher","first-page":"4011","DOI":"10.1200\/JCO.2024.42.16_suppl.4011","volume":"42","author":"J Hao","year":"2024","unstructured":"Hao J, et al. Safety and efficacy of IBI389, an anti-CLDN18.2\/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: preliminary results from a phase 1 study. J Clin Oncol. 2024;42:4011\u20134011.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1352_CR139","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ymthe.2016.11.006","volume":"25","author":"E Dheilly","year":"2017","unstructured":"Dheilly E, et al. Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther. 2017;25(2):523\u201333.","journal-title":"Mol Ther"},{"key":"1352_CR140","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1158\/1538-7445.AM2022-4260","volume":"82","author":"J Li","year":"2022","unstructured":"Li J, et al. Abstract 4260: PT886, an anti-claudin18.2\/anti-CD47 bispecific antibody constructed with the PACbody and SPECpair technology platforms, exhibits robust anti-tumor activity in a pancreatic cancer xenograft model. Cancer Res. 2022;82:4260\u20134260.","journal-title":"Cancer Res"},{"key":"1352_CR141","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1200\/JCO.23.02314","volume":"42","author":"C Qi","year":"2024","unstructured":"Qi C, et al. Safety and efficacy of CT041 in patients with refractory metastatic pancreatic cancer: A pooled analysis of two Early-Phase trials. J Clin Oncol. 2024;42:2565\u201377.","journal-title":"J Clin Oncol"},{"key":"1352_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0103-y","volume":"4","author":"RE Hollingsworth","year":"2019","unstructured":"Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. Npj Vaccines. 2019;4: 7.","journal-title":"Npj Vaccines"},{"key":"1352_CR143","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JCO.2001.19.1.145","volume":"19","author":"EM Jaffee","year":"2001","unstructured":"Jaffee EM, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001;19:145\u201356.","journal-title":"J Clin Oncol"},{"key":"1352_CR144","first-page":"194","volume":"4","author":"EM Jaffee","year":"1998","unstructured":"Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am. 1998;4:194\u2013203.","journal-title":"Cancer J Sci Am"},{"key":"1352_CR145","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1200\/JCO.2014.57.4244","volume":"33","author":"DT Le","year":"2015","unstructured":"Le DT, et al. Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015;33:1325\u201333.","journal-title":"J Clin Oncol"},{"key":"1352_CR146","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","volume":"36","author":"DT Le","year":"2013","unstructured":"Le DT, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother. 2013;36:382\u20139.","journal-title":"J Immunother"},{"key":"1352_CR147","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1158\/1078-0432.CCR-20-1025","volume":"26","author":"AA Wu","year":"2020","unstructured":"Wu AA, et al. A phase II study of allogeneic GM-CSF-transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer. Clin Cancer Res. 2020;26:5129\u201339.","journal-title":"Clin Cancer Res"},{"key":"1352_CR148","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-2992","volume":"25","author":"DT Le","year":"2019","unstructured":"Le DT, et al. Results from a phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE study). Clin Cancer Res. 2019;25:5493\u2013502.","journal-title":"Clin Cancer Res"},{"key":"1352_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39196-9","volume":"14","author":"T Heumann","year":"2023","unstructured":"Heumann T, et al. A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma. Nat Commun. 2023;14: 3650.","journal-title":"Nat Commun"},{"key":"1352_CR150","doi-asserted-by":"publisher","DOI":"10.1172\/JCI156211","author":"AL Huff","year":"2022","unstructured":"Huff AL, Jaffee EM, Zaidi N. Messenger RNA vaccines for cancer immunotherapy: progress promotes promise. J Clin Invest. 2022. https:\/\/doi.org\/10.1172\/JCI156211.","journal-title":"J Clin Invest"},{"key":"1352_CR151","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas LA, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144\u201350.","journal-title":"Nature"},{"key":"1352_CR152","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08508-4","author":"Z Sethna","year":"2025","unstructured":"Sethna Z, et al. RNA neoantigen vaccines prime long-lived CD8\u2009+\u2009t cells in pancreatic cancer. Nature. 2025. https:\/\/doi.org\/10.1038\/s41586-024-08508-4.","journal-title":"Nature"},{"key":"1352_CR153","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1200\/JCO.23.02585","volume":"42","author":"FR van \u2018t Land","year":"2024","unstructured":"van \u2018t Land FR, et al. Dendritic Cell-Based immunotherapy in patients with resected pancreatic cancer. J Clin Oncol. 2024;42:3083\u201393.","journal-title":"J Clin Oncol"},{"key":"1352_CR154","unstructured":"Elicio therapeutics presents updated results from ELI-002 phase 1 AMPLIFY-201 study at ESMO immuno-oncology congress 2024. https:\/\/elicio.com\/press_releases\/elicio-therapeutics-presents-updated-results-from-eli-002-phase-1-amplify-201-study-at-esmo-immuno-oncology-congress-2024. Accessed 20 Aug 2025."},{"key":"1352_CR155","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner R, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022;386:2112\u20139.","journal-title":"N Engl J Med"},{"key":"1352_CR156","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64\u201373.","journal-title":"N Engl J Med"},{"key":"1352_CR157","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.omto.2022.01.010","volume":"24","author":"D Yeo","year":"2022","unstructured":"Yeo D, Giardina C, Saxena P, Rasko JE. J. The next wave of cellular immunotherapies in pancreatic cancer. Mol Therapy - Oncolytics. 2022;24:561\u201376.","journal-title":"Mol Therapy - Oncolytics"},{"key":"1352_CR158","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.2024.42.16_suppl.3002","volume":"42","author":"W Park","year":"2024","unstructured":"Park W, et al. Phase I\/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors. J Clin Oncol. 2024;42:3002\u20133002.","journal-title":"J Clin Oncol"},{"key":"1352_CR159","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41575-021-00431-7","volume":"18","author":"J Encarnaci\u00f3n-Rosado","year":"2021","unstructured":"Encarnaci\u00f3n-Rosado J, Kimmelman AC. Harnessing metabolic dependencies in pancreatic cancers. Nat Rev Gastroenterol Hepatol. 2021;18:482\u201392.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1352_CR160","unstructured":"Rafael pharmaceuticals provides update on pivotal phase 3 clinical trial in patients with metastatic pancreatic cancer. 2021. https:\/\/www.globenewswire.com\/news-release\/2021\/10\/28\/2322715\/28235\/en\/Rafael-Pharmaceuticals-Provides-Update-on-Pivotal-Phase-3-Clinical-Trial-in-Patients-with-Metastatic-Pancreatic-Cancer-and-Interim-Analysis-of-Pivotal-Phase-3-Clinical-Trial-in-Pat.html. Accessed 20 Aug 2025."},{"key":"1352_CR161","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/2159-8290.CD-17-0952","volume":"8","author":"A Yang","year":"2018","unstructured":"Yang A, et al. Autophagy sustains pancreatic cancer growth through both cell-autonomous and nonautonomous mechanisms. Cancer Discov. 2018;8:276\u201387.","journal-title":"Cancer Discov"},{"key":"1352_CR162","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto K, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581:100\u20135.","journal-title":"Nature"},{"key":"1352_CR163","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature14587","volume":"524","author":"RM Perera","year":"2015","unstructured":"Perera RM, et al. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. Nature. 2015;524:361\u20135.","journal-title":"Nature"},{"key":"1352_CR164","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1158\/1078-0432.CCR-19-4042","volume":"26","author":"HJ Zeh","year":"2020","unstructured":"Zeh HJ, et al. A randomized phase II preoperative study of autophagy inhibition with high-dose hydroxychloroquine and gemcitabine\/nab-paclitaxel in pancreatic cancer patients. Clin Cancer Res. 2020;26:3126\u201334.","journal-title":"Clin Cancer Res"},{"key":"1352_CR165","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1001\/jamaoncol.2019.0684","volume":"5","author":"TB Karasic","year":"2019","unstructured":"Karasic TB, et al. Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:993\u20138.","journal-title":"JAMA Oncol"},{"key":"1352_CR166","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1200\/JCO.2021.39.3_suppl.404","volume":"39","author":"GA Manji","year":"2021","unstructured":"Manji GA, et al. ARC-8: phase i\/ib study to evaluate safety and tolerability of AB680\u2009+\u2009chemotherapy\u2009+\u2009zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC). J Clin Oncol. 2021;39:404\u2013404.","journal-title":"J Clin Oncol"},{"key":"1352_CR167","doi-asserted-by":"publisher","first-page":"S484","DOI":"10.1016\/j.annonc.2024.08.671","volume":"35","author":"AG Sacher","year":"2024","unstructured":"Sacher AG, et al. 604O phase I dose escalation and initial dose expansion results of AMG 193: A MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors. Ann Oncol. 2024;35:S484\u20135.","journal-title":"Ann Oncol"},{"key":"1352_CR168","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114981","volume":"211","author":"J Rodon","year":"2024","unstructured":"Rodon J, et al. 503LBA LBA orals: results from CA240-0007, a phase 1\/2 multiple expansion cohort study of BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del). Eur J Cancer. 2024;211: 114981.","journal-title":"Eur J Cancer"},{"key":"1352_CR169","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.pan.2021.03.018","volume":"21","author":"J Zhao","year":"2021","unstructured":"Zhao J, et al. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival. Pancreatology. 2021;21:942\u20139.","journal-title":"Pancreatology"},{"key":"1352_CR170","doi-asserted-by":"publisher","first-page":"S519","DOI":"10.1016\/j.annonc.2024.08.725","volume":"35","author":"ZA Wainberg","year":"2024","unstructured":"Wainberg ZA, et al. 659P combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer. Ann Oncol. 2024;35:S519\u201320.","journal-title":"Ann Oncol"},{"key":"1352_CR171","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4161\/cbt.4.1.1380","volume":"4","author":"SR Hustinx","year":"2005","unstructured":"Hustinx SR, et al. Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. Cancer Biol Ther. 2005;4:83\u20136.","journal-title":"Cancer Biol Ther"},{"key":"1352_CR172","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1200\/JCO.2022.40.4_suppl.604","volume":"40","author":"N Ngoi","year":"2022","unstructured":"Ngoi N, et al. Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on Methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss). J Clin Oncol. 2022;40:604\u2013604.","journal-title":"J Clin Oncol"},{"key":"1352_CR173","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1126\/science.aad5214","volume":"351","author":"GV Kryukov","year":"2016","unstructured":"Kryukov GV, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351:1214\u20138.","journal-title":"Science"},{"key":"1352_CR174","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev-cancerbio-030419-033444","volume":"5","author":"K Marjon","year":"2021","unstructured":"Marjon K, Kalev P, Marks K, Cancer Dependencies. PRMT5 and MAT2A in MTAP\/p16-Deleted cancers. Annual Rev Cancer Biology. 2021;5:371\u201390.","journal-title":"Annual Rev Cancer Biology"},{"key":"1352_CR175","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.151353","author":"F Orben","year":"2022","unstructured":"Orben F, et al. Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype. JCI Insight. 2022. https:\/\/doi.org\/10.1172\/jci.insight.151353.","journal-title":"JCI Insight"},{"key":"1352_CR176","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41388-021-02132-6","volume":"41","author":"RJ King","year":"2022","unstructured":"King RJ, et al. CD73 induces GM-CSF\/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. Oncogene. 2022;41:971\u201382.","journal-title":"Oncogene"},{"key":"1352_CR177","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","volume":"35","author":"J Rodon","year":"2024","unstructured":"Rodon J, et al. First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Ann Oncol. 2024;35:1138\u201347.","journal-title":"Ann Oncol"},{"key":"1352_CR178","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00109-018-01742-0","volume":"97","author":"L Zhou","year":"2019","unstructured":"Zhou L, et al. The distinct role of CD73 in the progression of pancreatic cancer. J Mol Med (Berl). 2019;97:803\u201315.","journal-title":"J Mol Med (Berl)"},{"key":"1352_CR179","unstructured":"Tango therapeutics reports positive 462 clinical data and provides update on development program. 2024. https:\/\/tangotx.gcs-web.com\/news-releases\/news-release-details\/tango-therapeutics-reports-positive-tng462-clinical-data-and. Accessed 20 Aug 2025."},{"key":"1352_CR180","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08031-z","volume":"21","author":"QP Janssen","year":"2021","unstructured":"Janssen QP, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer. 2021;21: 300.","journal-title":"BMC Cancer"},{"key":"1352_CR181","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2309","author":"DH Ahn","year":"2022","unstructured":"Ahn DH, Bekaii-Saab T. The continued struggle for defining a role for radiotherapy in pancreas cancer. JAMA Oncol. 2022. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2309.","journal-title":"JAMA Oncol"},{"key":"1352_CR182","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1200\/JCO.20.03329","volume":"39","author":"L Dahan","year":"2021","unstructured":"Dahan L, et al. Randomized phase II trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the PANOPTIMOX-PRODIGE 35 trial. J Clin Oncol. 2021;39:3242\u201350.","journal-title":"J Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01352-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01352-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01352-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:04:31Z","timestamp":1759997071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01352-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":182,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1352"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01352-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"16 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chengwei Peng: Consulting or Advisory Role - AbbVie. Paul Oberstein: Consulting or Advisory Role - Amal Therapeutics; AstraZeneca; Ipsen; Janssen Oncology; Loxo\/Lilly. Speakers\u2019 Bureau - AstraZeneca. Research Funding - Amal Therapeutics (Inst); Arcus Biosciences (Inst); Merck (Inst); Novartis (Inst); Roche\/Genentech (Inst); Zai Lab (Inst). Expert Testimony - Ipsen. Travel, Accommodations, Expenses \u2013 Merck.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}